Marta Figueiredo, PhD,  managing science editor—

Researchers have discovered that C9orf72 — the gene whose mutated version is associated with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) — works by activating key proteins for the transport and degradation of molecules inside the cell, in normal conditions. This discovery expands knowledge on how C9orf72 may contribute to the…

Voyager Therapeutics’ experimental therapy VY-SOD102 shows promise for treating patients with familial amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene, according to results in animal models. The preclinical data were presented at the Congress of the European Society of Gene and Cell Therapy…

Researchers have discovered that mast cells and neutrophils — two types of immune cells — are involved in the degeneration of peripheral motor nerve cells and progression of amyotrophic lateral sclerosis (ALS). These findings also clarify why masitinib — an investigational therapy for ALS that targets mast cells…

Adding Azilect (rasagiline) — a medication already approved to treat Parkinson’s disease — to Rilutek (riluzole) may be able to slow the advancement of fast-progressing amyotrophic lateral sclerosis (ALS), a Phase 2 trial suggests. However, its positive safety results are being challenged by other physicians, who raise concerns that…

Requip (ropinirole), a medication already approved to treat Parkinson’s disease, may be a potential therapeutic agent for amyotrophic lateral sclerosis (ALS), according to a preclinical study. The study, “Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent,” was published in the journal…

The balance between copper isotopes (variants) – but not copper levels – is disrupted in patients with amyotrophic lateral sclerosis (ALS), according to a recent study. Copper isotope composition potentially may be used as a biomarker of ALS, distinguishing it from other neurodegenerative diseases, such as Alzheimer’s. The study, “…

An exploratory anti-cancer therapy may halt the characteristic toxic accumulation of TDP-43 in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), researchers suggest. The preclinical study, “Poly(ADP-Ribose) Prevents Pathological Phase Separation of TDP-43 by Promoting Liquid Demixing and Stress Granule Localization,” was published in the journal…

Strong feelings of being sleepy during daytime hours are much more common in amyotrophic lateral sclerosis (ALS) patients than the general public, and appear to be associated with poorer cognitive skills and greater behavioral problems, a study from China reports. Its researchers suggested that their findings, if confirmed in larger studies,…

Gamisoyo-San (GSS), an herbal formula widely used in Asian countries to treat depression, anxiety and other conditions, significantly reduced inflammation and oxidative stress in mice in a study of amyotrophic lateral sclerosis (ALS), suggesting that GSS could be used as an alternative treatment with fewer side effects than conventional…

Sporadic and familial forms of amyotrophic lateral sclerosis (ALS) are associated with two microRNA molecules that are downregulated — meaning these molecules, involved in the protein production of certain genes, cause less protein to be created —, researchers have discovered. And they found a possible way of “upregulating” these molecules, making…